A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

The Elton John AIDS Foundation has announced that GRAMMY® Award nominated popstar and Midwest Princess Chappell Roan will ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...